On Friday, May 5th, NEWDIGS at Tufts Medical Center co-hosted a research symposium with fellow researchers and long-time collaborators from Utrecht University and Harvard Medical School (HMS). The event, titled Uncertainty … Read More
Meet Marcelien Callenbach, FoCUS visiting research fellow
At NEWDIGS we welcome the opportunity to be part of rising innovation leaders’ careers, so this spring we’re excited to welcome Marcelien Callenbach, MS as a visiting scholar. While at … Read More
Medicaid best price reforms to enable innovative payment models for cell and gene therapies
Expert Review of Pharmacoeconomics & Outcomes Research, 23(2), 191–203.Quinn, C., Ciarametaro, M., Sils, B., Phares, S., & Trusheim, M. Cell and gene therapies promise durable benefits but face financial challenges … Read More
FoCUS Monthly Recap: April 2022
RESEARCH BRIEF How can self-insured employers prepare for the portfolio impact of high-cost gene therapies coming to market? Self-insured employers currently rely on traditional stop-loss insurance to protect against unexpected … Read More
How can self-insured employers prepare for the portfolio impact of highcost gene therapies coming to market?
Self-insured employers (SIEs) currently rely on traditional stop-loss insurance to protect against unexpected high-cost claims, including those for cell and gene therapies. Given that current approvals are in rare diseases, … Read More
FoCUS Monthly Recap: February 2022
JUST RELEASED Paying for Cures Toolkit updated with new pipeline modeling and financing strategies FoCUS released an updated and expanded version of its Paying for Cures Toolkit, which is designed to … Read More
Data for modelling US projections of product approvals, patients treated, and product revenues for durable cell and gene therapies
Data in Brief, 41, 107891.Young, C. M., Trusheim, M., & Quinn, C. (2022). The recent marketing approval of several durable gene and cell therapies (2017-2020), together with observations that 7,000 … Read More
FoCUS Monthly Recap: January 2022
JUST RELEASED Paying for Cures Toolkit updated with new pipeline modeling and financing strategies Today FoCUS released an updated and expanded version of its Paying for Cures Toolkit, which is designed … Read More
Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues
Drug Discovery Today (2021). DOI: 10.1016/j.drudis.2021.09.001C. Young; C. Quinn; M. Trusheim. Durable cell and gene therapies potentially transform patient lives, but payers fear unsustainable costs arising from the more than … Read More
FoCUS Monthly Recap: December 2021
COMING SOON Paying for Cures Toolkit update in early ’22 After the holiday FoCUS will release a major update to the toolkit, including updates to the Pipeline and Individual Indication worksheets … Read More